))
Investment Strategies in Phage Therapy with Dr. Richard Alm at CARB-X
Manage episode 315364571 series 3287704
Contenuto fornito da Steven Yang. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Steven Yang o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator(CARB-X) is one global nonprofit partnership that manages a large portfolio of early stage companies to do the job as described by its name. In this episode, we are happy to have its chief scientist Dr. Richard Alm to help us paint a broad picture of the antimicrobial landscape and discuss their investment strategies related to phage therapy. The global biotech is a $800B dollar market this year, with a >15% CAGR, what can we do to promote the scientific understanding of phage and phage therapy in this capital driven economy?
Find out more about CARB-X at their website: https://carb-x.org
19 episodi
Condividi
